Nastech Appoints MDRNA, Inc. Directors Strategic Advi...( BOTHELL Wash. Feb. 5 /- Nastech P...),Health

BOTHELL, Wash., Feb. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. ("Nastech") (Nasdaq: NSTK) announced today that it has named members to the MDRNA, Inc. ("MDRNA") Directors Strategic Advisory Board that will provide scientific, financial and corporate governance expertise as Nastech moves to establish MDRNA, currently a wholly-owned subsidiary, as an independent company.

Advisory Board appointees include:

Susan B. Bayh, J.D. has been a director of Nastech since July 2005 as a member of the Compensation and chairman of the Nominating and Corporate Governance Committees of the Board of Directors. Mrs. Bayh currently serves on the boards of directors of Curis, Inc., a therapeutic drug development company, Dendreon Corporation, a therapeutic drug development company, Dyax Corp., a biopharmaceutical company, Emmis Communications, a diversified media company, and Wellpoint, Inc., a Blue Cross / Blue Shield company. In addition, Mrs. Bayh is a member of the Audit and Compensation Committees of the board of directors of Curis, Inc., and a member of the Compensation Committee of the board of directors of Emmis Communications. Previously, Mrs. Bayh also served on the boards of directors of Cubist Pharmaceuticals, Inc., a pharmaceutical company, from 2000 to 2004, and Esperion Therapeutics, Inc., a biopharmaceutical company, from 2000 to 2003. From 1994 to 2004, she was a Distinguished Visiting Professor at the College of Business Administration at Butler University in Indianapolis, Indiana. From 1994 to 2000, she was a Commissioner for the International Joint Commission of the Water Treaty Act between the United States and Canada. From 1989 to 1994, Mrs. Bayh served as an attorney in the Pharmaceutical Division of
'/>"/>